Cai, Xiaoling
Yang, Wenjia
Feng, Bo
Ji, Qiuhe
Liu, Ming
Li, Yanbing
Tong, Nanwei
Sun, Ningling
Zhao, Minghui
Ji, Linong
Funding for this research was provided by:
AstraZeneca Investment (China) Co., Ltd
Article History
Received: 24 November 2024
Accepted: 15 January 2025
First Online: 10 February 2025
Declarations
:
: Investigators of this research received a modest fee to cover their clinical service, clinical work, data collection and reporting. Investigator declare no other conflicts of financial interest for participation in this research.
: The study will be conducted in accordance with the Declaration of Helsinki, the Council for International Organizations of Medical Sciences International Ethical Guidelines, the applicable International Conference for Harmonisation Good Clinical Practice Guidelines, and all applicable laws and regulations. The study protocol was reviewed and approved by the Institutional Review Board/Independent Ethics Committee of Peking University People’s Hospital and each participating center before patient recruitment. The ethics committee reference number of Peking University People’s Hospital is 2023PHB063-001. All subjects must sign an informed consent form prior to their participation in the study.